Original Research
Published on 29 Mar 2023
Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
in Respiratory Pharmacology
- 4,366 views
- 5 citations